SPONSOR
Innovent Biologics (Suzhou) Co. Ltd.
Total Trials
2
Recruiting
2
Phases
Phase 2, Phase 1
Innovent Biologics (Suzhou) Co. Ltd. is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Melanoma, Small Cell Lung Cancer (SCLC).
The trial portfolio spans Phase 2, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Innovent Biologics (Suzhou) Co. Ltd.
How many clinical trials has Innovent Biologics (Suzhou) Co. Ltd. sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Innovent Biologics (Suzhou) Co. Ltd., of which 2 are actively recruiting participants. These trials cover conditions including Melanoma, Small Cell Lung Cancer (SCLC). Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Innovent Biologics (Suzhou) Co. Ltd. research focus on?
Innovent Biologics (Suzhou) Co. Ltd. clinical trials span Melanoma, Small Cell Lung Cancer (SCLC). The research pipeline includes Phase 2, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Innovent Biologics (Suzhou) Co. Ltd. clinical trial?
To participate in a Innovent Biologics (Suzhou) Co. Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Innovent Biologics (Suzhou) Co. Ltd. trials with current recruitment status updated daily.
Clinical Trials by Innovent Biologics (Suzhou) Co. Ltd.
NCT06797297 Phase 2
Recruiting
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
Melanoma
NCT07559019 Phase 1
Recruiting
Safety and Preliminary Activity of BI115 in Advanced SCLC
Small Cell Lung Cancer (SCLC)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology